ロード中...
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3616665/ https://ncbi.nlm.nih.gov/pubmed/23275151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgs393 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|